Contribution of [18F]DPA-714 PET for Grading and Exploration of the Inflammatory Microenvironment of Glioma. (INFLAGLI)

Center Eugene Marquis

Status: Withdrawn

Conditions: Glioma

Treatments: Drug: [18F]DPA-714

Study type: Interventional

Funder types: Other

Identifiers

NCT05672082

2022-1-58-002

Details and patient eligibility

About

The 18-kDa translocator protein (TSPO) is a mitochondrial protein that is weakly expressed in the healthy brain. However, there is an increase in the expression of TSPO in glial tumors. It is even associated with a higher malignancy and a shorter survival of patients. Among the different TSPO ligands, the most commonly used tracers in PET imaging are [18F]DPA-714 and 18F-GE180. We hypothesize that [18F]DPA-714 PET could improve the current performance for tumor grade definition in vivo, which is a major issue for the therapeutic management of gliomas.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age greater than or equal to 18 years
• Suspicion of an operable diffuse glioma
• Written informed consent (signed)
• Affiliated or beneficiary of a social security plan

Exclusion criteria

• Suspicion of grade I glioma
• Surgical urgency (less than 8 days between the suspected diagnosis and surgery)
• Pregnant or breastfeeding woman
• Persons deprived of liberty or under guardianship
• Impossibility to undergo the medical follow-up of the trial for geographical, social or psychological reasons

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

0 participants in 1 patient group

[18F]DPA-714 PET

Experimental group

Treatment:

Drug: [18F]DPA-714